Latest Breaking News On - Hedge funds weigh in on amneal pharmaceuticals - Page 1 : vimarsana.com

Amneal Pharmaceuticals, Inc (NASDAQ:AMRX) Receives $8 25 Consensus Target Price from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given an average rating of “Buy” by the four ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on […]

Piper sandlerNews ratings for amneal pharmaceuticals dailyAmneal pharmaceuticals company profileGoldman sachs groupAmneal pharmaceuticalsAmneal pharmaceuticals incAmneal pharmaceuticals stock downSherbrooke park advisersAtlanta consulting group advisorsHedge funds weigh in on amneal pharmaceuticalsGet free reportMarketbeat ratingsTruist financialCapital managementPark advisersConsulting group advisors

The Goldman Sachs Group Boosts Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $8 00

The Goldman Sachs Group Boosts Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $8 00
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesPiper sandlerNews ratings for amneal pharmaceuticals dailyConnor clark lunn investment management ltdHedge funds weigh in on amneal pharmaceuticalsAmneal pharmaceuticals incGoldman sachs groupAmneal pharmaceuticals stock performanceAmneal pharmaceuticalsCaxton associatesFree reportGet free reportInvestment managementLunn investment managementPublic employees retirement systemAmneal pharmaceuticals daily

Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Reaffirmed by Truist Financial

Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Reaffirmed by Truist Financial
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesPiper sandlerAmneal pharmaceuticals incAmneal pharmaceuticalsAmneal pharmaceuticals tradingNews ratings for amneal pharmaceuticals dailyVanguard group incGoldman sachs groupCharles schwab investment management incHedge funds weigh in on amneal pharmaceuticalsTruist financialFree reportGet free reportCapital managementSchwab investment managementTeacher retirement system

Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY23 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY23 Earnings Guidance
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

News ratings for amneal pharmaceuticals dailyHedge funds weigh in on amneal pharmaceuticalsCapital managementMorgan stanleyAmneal pharmaceuticals incAmneal pharmaceuticals stock performanceAmneal pharmaceuticals company profileVanguard group incMillennium managementAmneal pharmaceuticalsNorges bankGet free reportModerate buyAmneal pharmaceuticals daily

Amneal Pharmaceuticals, Inc (NASDAQ:AMRX) Receives $4 80 Average Target Price from Analysts

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price […]

Analyst recommendations for amneal pharmaceuticalsPanagora asset management incAmneal pharmaceuticalsMetlife investment managementNews ratings for amneal pharmaceuticals dailyAmneal pharmaceuticals price performanceHedge funds weigh in on amneal pharmaceuticalsAmneal pharmaceuticals incYork mellon corpSwiss national bankAmneal pharmaceuticals company profileBlackrock incGet free reportMarketbeat ratingsNational bankNew york mellon corp